About: Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy
Creator	Taraseviciute, Agne Abdel-Azim, Hisham Steiner, Marie Bollard, Catherine Martin, Paul »more»
source	PMC
abstract	In 2017, an autologous chimeric antigen receptor (CAR) T cell therapy indicated for children and young adults with relapsed and/or refractory CD19(+) acute lymphoblastic leukaemia became the first gene therapy to be approved in the USA. This innovative form of cellular immunotherapy has been associated with remarkable response rates but is also associated with unique and often severe toxicities, which can lead to rapid cardiorespiratory and/or neurological deterioration. Multidisciplinary medical vigilance and the requisite health-care infrastructure are imperative to ensuring optimal patient outcomes, especially as these therapies transition from research protocols to standard care. Herein, authors representing the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network Hematopoietic Stem Cell Transplantation (HSCT) Subgroup and the MD Anderson Cancer Center CAR T Cell Therapy-Associated Toxicity (CARTOX) Program have collaborated to provide comprehensive consensus guidelines on the care of children receiving CAR T cell therapy.
has issue date	2018-08-06(xsd:dateTime)
bibo:doi	10.1038/s41571-018-0075-2
bibo:pmid	30082906
has license	cc-by
sha1sum (hex)	376f733ce075bbbfb49d3cb24fffada63bee3293
schema:url	https://doi.org/10.1038/s41571-018-0075-2
resource representing a document's title	Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy
has PubMed Central identifier	PMC7096894
has PubMed identifier	30082906
schema:publication	Nat Rev Clin Oncol
resource representing a document's body	covid:376f733ce075bbbfb49d3cb24fffada63bee3293#body_text
is schema:about of	named entity 'paediatric' named entity 'chimeric antigen receptor T cell' named entity 'paediatric' named entity '2 years' named entity '1-8' »more»
is part of of	covid:376f733ce075bbbfb49d3cb24fffada63bee3293#body_text Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy In 2017, an autologous chimeric antigen receptor (CAR) T cell therapy indicated for children and young adults with relapsed and/or refractory CD19(+) acute lymphoblastic leukaemia became the first gene therapy to be approved in the USA. This innovative form of cellular immunotherapy has been associated with remarkable response rates but is also associated with unique and often severe toxicities, which can lead to rapid cardiorespiratory and/or neurological deterioration. Multidisciplinary medical vigilance and the requisite health-care infrastructure are imperative to ensuring optimal patient outcomes, especially as these therapies transition from research protocols to standard care. Herein, authors representing the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network Hematopoietic Stem Cell Transplantation (HSCT) Subgroup and the MD Anderson Cancer Center CAR T Cell Therapy-Associated Toxicity (CARTOX) Program have collaborated to provide comprehensive consensus guidelines on the care of children receiving CAR T cell therapy.

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software